Key takeaways
- New studies on peptides like Retatrutide and Tirzepatide show promising results.
- Research on VIP highlights its role in immunometabolism and neuroinflammation.
- Tirzepatide and Semaglutide are being compared in terms of cardiovascular outcomes.
- The future of obesity treatment may involve new peptide-based therapies.
The past week has seen a surge in new studies on peptides, with a focus on their potential in treating various conditions, including obesity and type 2 diabetes. One of the most notable studies is on Retatrutide, a triple-hormone agonist that has shown promising results in reducing body weight and improving lipid profiles.
Another peptide that has been making headlines is Tirzepatide, a dual GIP/GLP-1 agonist that has been shown to be effective in reducing body weight and improving glycemic control. A recent study compared the cardiovascular outcomes of Tirzepatide and Semaglutide, another popular peptide-based therapy.
Retatrutide's phase 3 weight-loss numbers
{{retatrutide}} Retatrutide has been shown to produce significant weight loss in phase 3 trials, with an average weight loss of over 20% in some studies. This is a promising result, especially considering the limited treatment options available for obesity.
Tirzepatide's cardiovascular benefits
{{tirzepatide}} Tirzepatide has been shown to have cardiovascular benefits, including reducing the risk of major adverse cardiovascular events. A recent study compared the cardiovascular outcomes of Tirzepatide and Semaglutide, finding that both peptides had similar benefits.
VIP's role in immunometabolism
{{vip}} Vasoactive intestinal peptide (VIP) has been shown to play a role in immunometabolism and neuroinflammation. A recent review highlighted the potential of VIP in treating conditions such as obesity and diabetes.
Comparison of peptides
| Peptide | What it is | FDA status | Evidence | Half-life | Banned in sport |
|---|---|---|---|---|---|
| Retatrutide | Triple-hormone agonist | Not FDA-approved | 4 | 6 days | yes |
| Tirzepatide | Dual GIP/GLP-1 agonist | FDA-approved | 5 | 5 days | no |
| Semaglutide | GLP-1 receptor agonist | FDA-approved | 5 | 7 days | no |
| VIP | Natural hormone | Not FDA-approved | 3 | 2 minutes | no |
The bottom line
The new studies on peptides like Retatrutide and Tirzepatide show promising results, and the future of obesity treatment may involve new peptide-based therapies. However, more research is needed to fully understand the potential benefits and risks of these peptides.
This is educational information, not medical advice.
Sources
- Pharmacy students' knowledge and attitudes regarding GLP-1 receptor agonist adverse effects in obesity management: a cross-sectional study — The Libyan journal of medicine, 2026/12/31
- Delays in access to generic semaglutide point to key missing pieces in Canada's drug approval system — Health policy (Amsterdam, Netherlands), 2026/12/01
- Tirzepatide attenuates cardiac microvascular injury and ferroptosis-related lipid peroxidation in diabetic mice: endothelial responses in the context of partial PRKN silencing — European journal of pharmacology, 2026/11/25
- Glucose-dependent insulinotropic polypeptide (GIP) signaling in visceral and subcutaneous adipose tissue: implications for obesity and metabolic disease-a narrative review with a structured literature search — Reviews in endocrine & metabolic disorders, 2026/10/22
- Calcium-Binding Protein Expression Cannot Serve as a General Classifier for GABAergic Neurons in the Macaque Cortex — The Journal of neuroscience : the official journal of the Society for Neuroscience, 2026/10/21
- Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea — The New England journal of medicine, 2026/10/21
- Economic evaluation of tirzepatide, semaglutide, and liraglutide in the treatment of obese and overweight patients without diabetes: a short-term cost-effectiveness analysis in Iran — Journal of diabetes and metabolic disorders, 2026/10/17
- Medical treatments for obesity: what does the future have in store? — The Journal of clinical endocrinology and metabolism, 2026/10/16
- Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes — The Journal of clinical endocrinology and metabolism, 2026/10/16
- Retatrutide treatment in streptozotocin-induced diabetic rats: renal inflammatory cytokines, HIF‑1α expression, and histopathological injury profile — Journal of molecular histology, 2026/10/15
- Neuropeptides in Immunometabolism and Neuroinflammation: Insights from Traditional Chinese Medicine — Neuroendocrinology, 2026/10/12
- The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications — Journal of diabetes and metabolic disorders, 2026/10/12
- 12-month weight-loss trajectories and predictors of response to tirzepatide under individualized dosing: A multicenter real-world study — Obesity pillars, 2026/10/12
- Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes — Journal of diabetes and metabolic disorders, 2026/10/05
- Influence of exogenous glucagon-like peptide 2 on mechanisms of enteric neurotransmitter-mediated vasorelaxation in the isolated bovine mesenteric artery and vein — Physiological reports, 2026/10/01
- Types of Neurons in the Myenteric Plexus of Human Gastric Corpus Identified by Multi-Layer Immunohistochemical Coding and Vagal Tracing — Neurogastroenterology and motility, 2026/10/01
- Sex-Dependent Alterations in Behavioral Development of Mice Lacking α5-Nicotinic Acetylcholine Receptors — Journal of neuroscience research, 2026/10/01
- Composite pheochromocytoma-ganglioneuroma secreting vasoactive intestinal peptide — Endocrinology, diabetes & metabolism case reports, 2026/10/01
